Linker Information
General Information of This Linker
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
CN117337196A Compound93 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ -5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line Calu6 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 0% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 5% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 7% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 8% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 18% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 18% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line Calu6 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 25% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 28% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 30% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 35% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 38% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line T47D cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 38% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line Calu6 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 45% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Gastric adenocarcinoma | HS746T cells | CVCL_0333 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 60% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 75% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line U87.MG cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
CN117337196A Compound87 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 30% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 40% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 42% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 50% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
CN117337196A Compound94 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive c-Met expression (c-Met+++/++) | ||
| Method Description |
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 25% | Positive c-Met expression (c-Met+++/++) | ||
| Method Description |
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 35% | Positive c-Met expression (c-Met+++/++) | ||
| Method Description |
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 45% | Positive c-Met expression (c-Met+++/++) | ||
| Method Description |
c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC3 cells | CVCL_0186 | ||
CN117337196A Compound86 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio |
60-80 %
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Her2-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3000 cells/well and treated with the compound 86 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||